Anixa Biosciences (ANIX) investor relations material

Business overview and financials

• Clinical-stage company focused on developing first-in-class cancer therapies and vaccines.

• Maintains a strong balance sheet with $14M in cash and short-term investments as of January 31, 2026.

• Operates a capital-efficient model with an annual cash burn of $5-7M and no debt, warrants, or preferred stock.

• Consistent insider buying and a clean capital table support investor confidence.

CAR-T program for ovarian cancer

• Lead program, Lira-cel, is a CAR-T therapy targeting FSHR, primarily expressed in ovarian tissue and tumor vasculature.

• Dual mechanism: direct tumor cell killing and anti-angiogenesis by targeting tumor blood vessels.

• Intraperitoneal delivery enhances tumor targeting and reduces systemic side effects.

• Phase 1 clinical trial in recurrent/chemoresistant ovarian cancer underway, with multiple dose-escalation cohorts.

• Positive survival trends observed in treated patients, with ongoing data collection.

Breast cancer vaccine program

• Vaccine targets α-lactalbumin, a retired tissue-specific protein re-expressed in triple negative breast cancer (TNBC).

• Preclinical studies show 100% prevention of breast cancer in vaccinated mice with no significant autoimmune effects.

• Phase 1 trial completed: 35 patients dosed, strong immune responses, no safety concerns, and successful combination with Keytruda.

• Phase 2 trial planned in the neo-adjuvant setting to accelerate efficacy evaluation and potential pharma partnerships.